Aquestive Therapeutics, Inc. (AQST) financial statements (2023 and earlier)

Company profile

Business Address 30 TECHNOLOGY DRIVE
WARREN, NJ 07059
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 31,80749,32660,599
Cash and cash equivalents 31,80749,32660,599
Receivables3,0873,0814,36333
Inventory, net of allowances, customer advances and progress billings4,0382,4612,8595,441
Inventory4,0382,4612,8595,441
Deferred costs  1495,232
Other undisclosed current assets40,1347,27611,6172,896
Total current assets:47,25944,62568,31474,201
Noncurrent Assets
Operating lease, right-of-use asset2,7253,448 
Property, plant and equipment5,0556,8739,72612,207
Intangible assets, net (including goodwill)51102153204
Intangible assets, net (excluding goodwill)51102153204
Other noncurrent assets6,9037,836286239
Total noncurrent assets:14,73418,25910,16512,650
TOTAL ASSETS:61,99362,88478,47986,851
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,05015,65817,74927,631
Accounts payable8,3147,08912,27420,436
Accrued liabilities8,7368,5695,4757,195
Deferred revenue765693806
Debt2,0252,575 4,600
Other undisclosed current liabilities2,1242,178 721
Total current liabilities:21,96421,10418,55532,952
Noncurrent Liabilities
Long-term debt and lease obligation53,49737,17560,33842,603
Long-term debt, excluding current maturities51,55134,32960,33842,603
Operating lease, liability1,9462,846 
Liabilities, other than long-term debt9,6075,5785,7081,216
Deferred revenue7,1223,6334,348
Asset retirement obligations  1,3601,216
Other liabilities2,4851,945  
Other undisclosed noncurrent liabilities59,05947,524  
Total noncurrent liabilities:122,16390,27766,04643,819
Total liabilities:144,127111,38184,60176,771
Stockholders' equity
Stockholders' equity attributable to parent(82,134)(48,497)(6,122)10,080
Common stock41353425
Additional paid in capital174,621137,725124,31871,431
Accumulated deficit(256,796)(186,257)(130,474)(61,376)
Total stockholders' equity:(82,134)(48,497)(6,122)10,080
TOTAL LIABILITIES AND EQUITY:61,99362,88478,47986,851

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues50,83245,84952,60967,430
Cost of revenue
(Cost of Goods and Services Sold)
 (12,964)  
Gross profit:50,83232,88552,60967,430
Operating expenses(85,511)(75,778)(105,277)(116,364)
Operating loss:(34,679)(42,893)(52,668)(48,934)
Nonoperating income (expense) 132 (5)
Investment income, nonoperating 132  
Other nonoperating expense   (5)
Interest and debt expense(23,871)(11,064)(14,214)(7,711)
Loss from continuing operations before equity method investments, income taxes:(58,550)(53,825)(66,882)(56,650)
Other undisclosed income (loss) from continuing operations before income taxes(11,989)(1,958)636(4,726)
Net loss available to common stockholders, diluted:(70,539)(55,783)(66,246)(61,376)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(70,539)(55,783)(66,246)(61,376)
Comprehensive loss, net of tax, attributable to parent:(70,539)(55,783)(66,246)(61,376)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: